Should a patient with acute ischemic stroke who cannot receive thrombolysis be treated with aspirin alone or with aspirin plus clopidogrel?

Antiplatelet Management for Acute Ischemic Stroke Without Thrombolysis

For patients with acute ischemic stroke who are not candidates for thrombolysis, aspirin alone should be given immediately if the stroke is moderate-to-severe (NIHSS > 3), but aspirin plus clopidogrel should be given if the stroke is minor (NIHSS ≤ 3) and treatment can be initiated within 24 hours of symptom onset. 1, 2

Critical First Step: Confirm Absence of Hemorrhage

• All patients must undergo immediate brain imaging (non-contrast CT or MRI) to exclude intracranial hemorrhage before any antiplatelet therapy is administered. 3
• Aspirin is absolutely contraindicated in suspected or confirmed intracerebral hemorrhage. 3
• A dysphagia screening must be performed and passed before oral antiplatelet administration. 2, 3

Treatment Algorithm Based on Stroke Severity

For Minor Stroke (NIHSS ≤ 3) Presenting Within 24 Hours

Dual antiplatelet therapy is superior to aspirin alone and should be initiated immediately: 1, 2, 4

• Loading doses: Aspirin 160-325 mg PLUS clopidogrel 300-600 mg 2, 5, 4
• Maintenance: Continue aspirin 75-100 mg daily PLUS clopidogrel 75 mg daily for exactly 21 days 2, 4
• After 21 days: Discontinue aspirin and continue clopidogrel 75 mg daily indefinitely 2

Evidence supporting this approach:

• The CHANCE trial demonstrated that dual antiplatelet therapy reduced stroke recurrence from 11.7% to 8.2% at 90 days when initiated within 24 hours, with no increase in hemorrhagic complications (0.3% in both groups). 4
• The POINT trial confirmed benefit but showed increased major bleeding when dual therapy was extended to 90 days (0.9% vs 0.4%), which is why the 21-day duration is preferred. 2, 5
• Treatment within 12 hours provides even greater benefit, reducing recurrent ischemic stroke from 8.91% to 6.57%. 6

For Minor Stroke (NIHSS ≤ 3) Presenting 24-72 Hours After Onset

Dual antiplatelet therapy may still be considered but with increased bleeding risk: 7

• The INSPIRES trial showed that clopidogrel plus aspirin initiated within 72 hours reduced new stroke (7.3% vs 9.2%) but increased moderate-to-severe bleeding (0.9% vs 0.4%). 7
• Use the same loading and maintenance regimen as above, but weigh the bleeding risk more carefully. 7

For Moderate-to-Severe Stroke (NIHSS > 3)

Aspirin monotherapy is the only recommended antiplatelet strategy: 1, 2

• Loading dose: Aspirin 160 mg immediately after imaging confirms no hemorrhage 1, 2
• Maintenance: Aspirin 81-325 mg daily indefinitely 1
• Dual antiplatelet therapy is NOT recommended because evidence is limited to minor strokes and bleeding risk (particularly hemorrhagic transformation) is substantially higher in moderate-to-severe strokes. 2

Alternative monotherapy options if aspirin is contraindicated: 1

• Clopidogrel 75 mg daily (preferred alternative) 1
• Aspirin 25 mg plus extended-release dipyridamole 200 mg twice daily 1

Special Considerations

Patients Already on Aspirin at Stroke Onset

• There is no evidence that increasing the aspirin dose or switching agents improves outcomes. 2
• Continue the current aspirin regimen; do not add clopidogrel for moderate-to-severe strokes. 2
• For minor strokes (NIHSS ≤ 3), adding clopidogrel may still be considered despite pre-existing aspirin use. 2

Patients With Dysphagia

• Aspirin 80 mg and clopidogrel 75 mg can be administered via enteral tube. 2
• Aspirin 325 mg rectal suppository is an alternative route. 2

Atrial Fibrillation

• If the stroke is cardioembolic due to atrial fibrillation, oral anticoagulation (not antiplatelet therapy) is the preferred long-term treatment. 1
• Bridge with aspirin until anticoagulation reaches therapeutic levels, typically starting anticoagulation 1-2 weeks post-stroke depending on infarct size and hemorrhagic transformation risk. 1

Common Pitfalls to Avoid

• Never administer aspirin based solely on clinical suspicion without imaging confirmation of no hemorrhage. 3
• Never extend dual antiplatelet therapy beyond 21-30 days because bleeding risk increases (0.9% vs 0.4%) without additional stroke reduction. 2, 5
• Never extrapolate dual antiplatelet therapy benefits to NIHSS > 3 strokes—the pivotal CHANCE and POINT trials excluded these patients, and hemorrhagic transformation risk is substantially higher. 2, 4, 5
• Never discontinue both antiplatelet agents simultaneously after the 21-day dual therapy period—continue clopidogrel monotherapy indefinitely for secondary prevention. 2
• Never use platelet transfusion to reverse aspirin effect in confirmed intracerebral hemorrhage patients not undergoing surgery, as this may worsen outcomes. 3

Clopidogrel Pharmacogenetics

• Clopidogrel is a prodrug requiring conversion by CYP2C19 to its active metabolite. 8
• Patients who are CYP2C19 poor metabolizers (homozygous for nonfunctional alleles) form less active metabolite and have reduced antiplatelet effect. 8
• Consider alternative P2Y12 inhibitors in identified poor metabolizers. 8
• Avoid concomitant omeprazole or esomeprazole, which significantly reduce clopidogrel's antiplatelet activity. 8

Timing Relative to Thrombolysis

If the patient received IV thrombolysis but it failed or was only partially effective:

• Delay all antiplatelet therapy for ≥24 hours after tPA administration. 2, 3
• Obtain a 24-hour post-tPA brain scan to exclude hemorrhagic transformation before starting any antiplatelet agent. 2, 3
• Initiating antiplatelet therapy within 24 hours of tPA is contraindicated. 2, 3